FDAnews
www.fdanews.com/articles/85201-repligen-begins-trial-of-rg2417-for-bipolar-disorder

REPLIGEN BEGINS TRIAL OF RG2417 FOR BIPOLAR DISORDER

March 10, 2006

Repligen has commenced a Phase II clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

Bipolar disorder, also known as manic depression, is an illness marked by extreme changes in mood, thought, energy and behavior in which a person's mood can alternate between the "poles" of mania and depression.

In this multicenter, dose escalating study 80 patients will receive either RG2417 or a placebo for six weeks, and will be evaluated for the safety and effectiveness of RG2417 on the symptoms of bipolar depression.